Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs CORT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CORT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

CORT Overall Winner 6-Pillar Tally: SYRE 0 – 5 CORT (1 Tie) Matrix Metrics: SYRE 3 – 7 CORT

As of Nov 16, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas CORT carries 50.7/100 (HOLD) at $69.17 (14.6x Forward P/E, 11.5% operating margin).

  • Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5); meanwhile CORT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs CORT
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70
CORT NASDAQ Head-to-Head Winner
Corcept Therapeutics Inc.
Pharmaceutical Preparations
$69.17
-5.17% 1D
Market Cap $8.1B
TTM Revenue $964M
Forward P/E 14.6x
Beta / 30D Vol 1.63β · 85% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 45.0 Fund 55.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.1%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $83.94 · SMA50: $102.85

6-Pillar Scorecard Institutional Category Breakdown (SYRE 0 – 5 CORT)

Columns: Metric · SYRE · CORT
1. Valuation Multiples CORT
Forward P/E N/M 14.6x
Trailing P/E N/M 55.4x
PEG Ratio N/M 0.81x
EV / Revenue N/M 8.3x
2. Growth & Scale CORT
Revenue Growth (YoY) +0.0% +64.0%
Earnings Growth (YoY) -99.7% +531.3%
TTM Revenue (USD) N/A $964M
Market Cap $9.8B $8.1B
3. Profitability & Quality CORT
Gross Margin N/A 98.5%
Operating Margin 0.0% 11.5%
Net Profit Margin 0.0% 16.8%
Return on Equity (ROE) -35.0% 22.1%
4. Balance Sheet & Cash Flow CORT
Cash Generation (TTM) N/A $195M
Cash Flow Margin N/A 20.2%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $90M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CORT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 87.9% (10th %ile) 53.1% (10th %ile)
Put/Call OI Skew N/A 0.41x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (3) vs CORT (7)
Institutional Metric SYRE CORT Criterion Row Edge
Market Capitalization
Scale
$9.8B $8.1B Larger Scale SYRE
Trailing P/E Ratio
Valuation
N/M 55.4x Lower Multiple CORT
Forward P/E Ratio
Valuation
N/M 14.6x Lower Multiple CORT
Revenue Growth (YoY)
Growth
+0.0% +64.0% Higher Growth CORT
Operating Margin (TTM)
Profitability
0.0% 11.5% Higher Margin CORT
Net Profit Margin
Profitability
0.0% 16.8% Higher Margin CORT
Return on Equity (ROE)
Capital Efficiency
-35.0% 22.1% Higher ROE CORT
52-Week Range Position
Momentum
88% ($22–$111) 42% ($29–$126) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 1.63β · 85% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
44.4 / 100 (HOLD) 50.7 / 100 (HOLD) Higher Composite CORT
Trailing 12M Revenue (USD)
Operating Scale
N/A $964M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 98.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.81x PEG · 8.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) $195M ($90M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +62.32 pp
SYRE: +25.11% · CORT: -37.21%
3M Horizon SYRE +34.14 pp
SYRE: -7.29% · CORT: -41.43%
6M Horizon SYRE +17.15 pp
SYRE: +42.64% · CORT: +25.49%
1Y Horizon SYRE +350.43 pp
SYRE: +341.74% · CORT: -8.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs CORT. Trailing 12-month operating profitability (SYRE 0.0% vs CORT 11.5%) and valuation multiples (SYRE N/M vs CORT 14.6x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
CORT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$964M
Gross Margin98.5%
Op. Margin11.5%
ROE / Fwd P/E22.1% · 14.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CORT CONSOLIDATION
109d in phase · OBV DISTRIBUTION
Current IV 53.1%
IV Percentile 10th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CORT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CORT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $8.1B market capitalization and 11.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs CORT Key Questions & Quantitative Answers

As of Nov 16, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas CORT carries 50.7/100 (HOLD) at $69.17 (14.6x Forward P/E, 11.5% operating margin). Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5); meanwhile CORT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CORT leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CORT at +64.0% YoY revenue growth and +531.3% YoY earnings growth on $964M TTM revenue (98.5% gross margin, 11.5% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $964M for CORT. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CORT.

CORT screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CORT trades at 14.6x Forward P/E, 55.4x Trailing P/E, 0.81x PEG, and 8.3x EV/Revenue (20.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus CORT (22.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, CORT carries 53.1% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.63β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.